August 26, 2008 17:19 ET

BioForce Nanosciences Announces Collaboration Agreement With UAlbany Nanocollege

AMES, IA--(Marketwire - August 26, 2008) - BioForce Nanosciences Holdings, Inc. (OTCBB: BFNH), a leader in systems integration at the micro- and nano-scales to create products for the life sciences, is pleased to announce that it has entered into a collaboration agreement with the College of Nanoscale Science and Engineering ("CNSE") of the University at Albany through which faculty, scientists and researchers at CNSE will utilize the BioForce Nano eNabler™ molecular printer for the development and evaluation of novel applications.

The UAlbany NanoCollege is the first college in the world dedicated to education, research, development, and deployment in the emerging disciplines of nanoscience, nanoengineering, nanobioscience, and nanoeconomics. CNSE's Albany NanoTech Complex -- a $4.2 billion, 450,000-square-foot megaplex that has attracted over 250 global corporate partners -- is regarded as the most advanced research complex at any university in the world.

Dr. Nathaniel Cady, Assistant Professor of Nanobioscience at CNSE, will lead the research efforts in collaboration with Assistant Professor of Nanobioscience Dr. Magnus Bergkvist. Work to be performed will focus on the development of novel polymeric Surface Patterning Tools™ (SPTs) for the direct printing of live cells. Surface Patterning Tools are the microfluidic dispensers used by the Nano eNabler to print materials on a surface. A secondary goal will be to evaluate and optimize the Nano eNabler system for printing molecules onto a variety of surface materials.

BioForce's Product Manager, Michael Lynch, said, "The CNSE is one of the most impressive nanotech facilities I have ever visited, and we are thrilled to be working with them. Professor Cady's exciting work is expanding the applications universe for the Nano eNabler system, and we look forward to bringing those advances to the life science market. A number of potential customers have inquired about the capability to directly print bacteria and eukaryotic cells with the Nano eNabler, and Dr. Cady's technology could make that a reality."

Dr. Alain E. Kaloyeros, Senior Vice President and Chief Executive Officer of CNSE, said, "The UAlbany NanoCollege is pleased to enter into this partnership with BioForce Nanosciences, a recognized leader in the integration of cutting-edge nanoscale technologies to foster innovations in the critical area of life sciences. Through this effort led by Professor Nathaniel Cady, CNSE will further expand its growing educational and research initiatives in the field of nanobioscience, which promises exciting new advances in the diagnosis, treatment and prevention of a myriad of diseases in the 21st century."

On Thursday, August 28 at 12:00pm EDT, Professor Cady will present his non-confidential research through a free BioForce-hosted online seminar. The title of his webinar presentation is "Biomolecular Printing for Biosensor and Biointerfacial Applications" and interested viewers may register to attend at www.bioforcenano.com or by clicking on this link.

About BioForce Nanosciences Holdings, Inc.

BioForce Nanosciences creates products and solutions for the life sciences by integrating biological and mechanical systems at the micro and nano scales. BioForce's flagship product, the Nano eNabler™ molecular printer, gives the Company and its customers a platform for development and discovery by printing tiny domains of biological materials on surfaces with nanometer spatial precision. BioForce technology is being used in areas such as biosensor functionalization; pattering and cell adhesion; and the printing of proteins to guide neural cell growth. For more information, visit www.bioforcenano.com or call 515-233-8333.

This news release contains forward-looking information that may be affected by certain risks and uncertainties, including those risks and uncertainties described in BioForce Nanosciences' most recent filings with the Securities and Exchange Commission. BioForce Nanosciences' actual results could differ materially from such forward-looking statements. BioForce assumes no duty to update these statements at any future date.